1. Cyhoeddwyd

   Orphan drugs revisited: author's response.

   Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol

   Hughes, D., Jenkinson, M. D., Gamble, C., Hartley, J. C., Hickey, H., Hughes, D. A., Blundell, M., Griffiths, M. J., Solomon, T. & Malluci, C. L., 3 Ion 2014, Yn: Trials. 15, 14

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

   Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

   Hughes, D., Hughes, D. A. & Walley, T., 1 Gorff 2003, Yn: Clinical Pharmacology and Therapeutics. 74, 1, t. 1-8

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

   Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

7. Cyhoeddwyd

   Charitable contributions to funding cancer services for children and young people in England and Wales

   Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2008, Yn: Journal of Child Health Care. 12, 2, t. 156-168

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

9. Cyhoeddwyd

   The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

   Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

10. Cyhoeddwyd

    Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

11. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

12. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence

    Hughes, D., Plumpton, C. O., Brown, I., Reuber, M., Marson, A. G. & Hughes, D. A., 26 Maw 2015, Yn: Epilepsy and Behavior. 45, t. 180-186

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

    Hughes, D., Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., Van Eker, D., Stevens, L., Hawkins, K., Toh, C. H., Kamali, F., Daly, A. K., Fitzmaurice, D., Coffey, A., Williamson, P. R., Park, B. K., Deloukas, P. & Pirmohamed, M., 1 Hyd 2009, Yn: Pharmacogenetics and Genomics. 19, 10, t. 800-812

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. Cyhoeddwyd

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Mai 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

18. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Hyd 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Cyhoeddwyd

    Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial

    Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

20. Cyhoeddwyd

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

21. Cyhoeddwyd

    The development of a QALY measure for epilepsy: NEWQOL-6D

    Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 Mai 2012, Yn: Epilepsy and Behavior. 24, 1, t. 36-43

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

24. Cyhoeddwyd

    The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

    Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

25. Cyhoeddwyd

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. Cyhoeddwyd

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

27. Cyhoeddwyd

    An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes

    Hughes, D., Farmer, A., Hardeman, W., Hughes, D. A., Prevost, A. T., Kim, Y., Craven, A., Oke, J., Boase, S., Selwood, M., Kellar, I., Graffy, J., Griffin, S., Sutton, S. & Kinmonth, A. L., 5 Ebr 2012, Yn: BMC Family Practice. 13, 30

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

28. Cyhoeddwyd

    Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.

    Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 Mai 2009, Yn: Pharmacoeconomics. 27, 8, t. 635-643

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

29. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

30. Cyhoeddwyd

    Defining rewardable innovation in drug therapy

    Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Ebr 2012, Yn: Nature Reviews Drug Discovery. 11, t. 253-254

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

31. Cyhoeddwyd

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

32. Cyhoeddwyd

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

35. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

36. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

37. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

38. Cyhoeddwyd

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

40. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

41. Cyhoeddwyd

    Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions

    Hughes, D., Roberts, E., Dawoud, D. M., Hughes, D. A. & Cefai, C., 1 Hyd 2015, Yn: International Journal of Pharmacy Practice. 23, 5, t. 333-339

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

42. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

43. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

44. Cyhoeddwyd

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

45. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

46. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

47. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

48. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

49. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

50. Cyhoeddwyd

    Engaging with the MRC Methodology Hubs – NWHTMR.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

51. Cyhoeddwyd

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

52. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

53. Cyhoeddwyd

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

54. Cyhoeddwyd

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

55. Cyhoeddwyd

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

56. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

57. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

58. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

59. Cyhoeddwyd

    Quantitative risk-benefit analysis

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

60. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

61. Cyhoeddwyd

    Warfarin pharmacogenetics: Economic considerations.

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 11, t. 899-902

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

62. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

63. Cyhoeddwyd

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

64. Cyhoeddwyd

    Multiple imputation of multiple multi-item scales when a full imputation model is infeasible

    Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Ion 2016, Yn: BMC Research Notes. 9, 45, t. 1-15

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

65. Cyhoeddwyd

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

66. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

67. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

68. Cyhoeddwyd

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

69. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

70. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

71. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

72. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

73. Cyhoeddwyd

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

74. Cyhoeddwyd

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

75. Cyhoeddwyd

    Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

    Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Hyd 2011, Yn: British Medical Journal. 343, t. 1-14

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

76. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

77. Cyhoeddwyd

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

78. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

79. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

80. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

81. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

82. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

83. Cyhoeddwyd

    Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

84. Cyhoeddwyd

    A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)

    Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, N. V., 9 Ion 2014, Yn: Trials. 15, 14

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

85. Cyhoeddwyd

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

86. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

87. Cyhoeddwyd

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

88. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

89. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

90. Cyhoeddwyd

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

91. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

92. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

93. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

94. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

95. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

96. Cyhoeddwyd

    Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.

    Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Maw 2012, Yn: Pharmacoeconomics.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

97. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

98. Cyhoeddwyd

    Is exercise effective in promoting mental well-being in older age? A systematic review.

    Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Awst 2010, Yn: Aging and Mental Health. 14, 6, t. 652-669

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

99. Cyhoeddwyd

    Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

    Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

100. Cyhoeddwyd

     The problem of orphan drugs

     Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Tach 2010, Yn: British Medical Journal. 341, t. 335-341

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid